GlassScriptPhysician profile
Summer Aldrugh
NPI 1083000723
$9,038.57
in general payments reported to CMS, 2019-2025
31 companies · $6,354 in 2025
The $6,354 reported for 2025 was more than what 85% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $280 · 2022: $450 · 2023: $777 · 2024: $1,178 · 2025: $6,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,000 · Food and Beverage: $2,546 · Travel and Lodging: $762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,000.00 |
| Food and Beverage | $2,546.06 |
| Travel and Lodging | $762.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recor Medical INC | $5,762.22 | 2025 | Paradise Ultrasound Renal Denervation System |
| Medtronic, INC. | $546.51 | 2021-2022 | |
| Pfizer INC. | $314.06 | 2023-2025 | |
| Amgen INC. | $289.32 | 2023-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $284.86 | 2022-2025 | Varithena Administration Pack, Bodyguardian, Cds - Mct/Cem Monitoring |
| Novartis Pharmaceuticals Corporation | $232.82 | 2023-2024 | |
| Endologix LLC | $203.75 | 2025 | Endocross Device, Torus Stent Graft System |
| Penumbra, INC. | $152.33 | 2023 | Indigo System |
| Alnylam Pharmaceuticals INC. | $146.82 | 2023-2025 | Onpattro |
| Philips North America LLC | $141.52 | 2023-2025 | (Ck4) Mcot, Event |
| Kiniksa Pharmaceuticals International, Plc | $100.74 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $100.61 | 2024-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $79.09 | 2023-2024 | Xarelto |
| Esperion Therapeutics, INC. | $78.35 | 2023-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $77.12 | 2023-2024 | Verquvo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $68.53 | 2023-2024 | Farxiga, Wainua |
| Atricure, INC. | $56.70 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Lexicon Pharmaceuticals, INC. | $54.53 | 2023-2024 | Inpefa |
| Abbott Laboratories | $43.90 | 2024 | Jot Dx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.72 | 2023-2024 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $39.31 | 2024 | Opsumit, Uptravi |
| Novo Nordisk INC | $38.69 | 2024 | Wegovy |
| Edwards Lifesciences Corporation | $27.48 | 2025 | Sapien 3 Ultra Resilia |
| Cvrx, INC. | $25.87 | 2023 | Barostim Neo System |
| Imperative Care, INC | $23.12 | 2025 | Symphony Catheter |
| Genzyme Corporation | $21.71 | 2023 | |
| Scpharmaceuticals INC. | $21.35 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $18.37 | 2023 | Arcalyst |
| Chiesi USA, INC. | $17.99 | 2024 | Kengreal |
| Bayer Healthcare Pharmaceuticals INC. | $15.85 | 2024 | |
| Shockwave Medical, INC | $13.33 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Summer Aldrugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.